Kymera Therapeutics (NASDAQ:KYMR) Research Coverage Started at BMO Capital Markets

BMO Capital Markets assumed coverage on shares of Kymera Therapeutics (NASDAQ:KYMR) in a research report released on Friday, Marketbeat.com reports. The firm issued a market perform rating and a $55.00 price objective on the stock.

A number of other research firms also recently weighed in on KYMR. Leerink Partners reaffirmed an “outperform” rating and set a $60.00 price target on shares of Kymera Therapeutics in a research report on Monday, September 9th. Morgan Stanley upped their price target on Kymera Therapeutics from $45.00 to $49.00 and gave the stock an “equal weight” rating in a research report on Wednesday, November 6th. Guggenheim upped their price target on Kymera Therapeutics from $45.00 to $52.00 and gave the stock a “buy” rating in a research report on Friday, November 1st. Oppenheimer increased their price objective on Kymera Therapeutics from $52.00 to $56.00 and gave the company an “outperform” rating in a report on Friday, September 27th. Finally, Wolfe Research raised Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $65.00 price objective for the company in a report on Monday, August 26th. Four analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Kymera Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $53.50.

Kymera Therapeutics Stock Performance

Shares of KYMR opened at $46.67 on Friday. The stock has a 50 day simple moving average of $46.40 and a 200 day simple moving average of $42.64. Kymera Therapeutics has a 52-week low of $21.20 and a 52-week high of $53.27. The firm has a market capitalization of $3.02 billion, a PE ratio of -19.94 and a beta of 2.16.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.01. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The business had revenue of $3.74 million during the quarter, compared to analyst estimates of $10.34 million. During the same period in the previous year, the firm earned ($0.90) EPS. Kymera Therapeutics’s quarterly revenue was down 20.9% compared to the same quarter last year. Equities research analysts predict that Kymera Therapeutics will post -2.79 EPS for the current fiscal year.

Insiders Place Their Bets

In other Kymera Therapeutics news, Director Pamela Esposito sold 13,500 shares of the stock in a transaction on Tuesday, September 17th. The stock was sold at an average price of $48.28, for a total transaction of $651,780.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 15.82% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Values First Advisors Inc. bought a new position in Kymera Therapeutics during the 3rd quarter worth $61,000. Quarry LP acquired a new stake in shares of Kymera Therapeutics during the 3rd quarter worth $95,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Kymera Therapeutics by 27.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock worth $114,000 after purchasing an additional 504 shares in the last quarter. Comerica Bank grew its holdings in shares of Kymera Therapeutics by 13.7% during the 1st quarter. Comerica Bank now owns 3,324 shares of the company’s stock worth $134,000 after purchasing an additional 400 shares in the last quarter. Finally, Public Employees Retirement Association of Colorado acquired a new stake in shares of Kymera Therapeutics during the 2nd quarter worth $139,000.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.